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Abstract
Microsystem-based technologies are providing new opportunities in the area of in vitro 
diagnostics due to their ability to provide process automation enabling point-of-care operation. As 
an example, microsystems used for the isolation and analysis of circulating tumor cells (CTCs) 
from complex, heterogeneous samples in an automated fashion with improved recoveries and 
selectivity are providing new opportunities for this important biomarker. Unfortunately, many of 
the existing microfluidic systems lack the throughput capabilities and/or are too expensive to 
manufacture to warrant their widespread use in clinical testing scenarios. Here, we describe a 
disposable, all-polymer, microfluidic system for the high-throughput (HT) isolation of CTCs 
directly from whole blood inputs. The device employs an array of high aspect ratio (HAR), 
parallel, sinusoidal microchannels (25 µm × 150 µm; W × D; AR = 6.0) with walls covalently 
decorated with anti-EpCAM antibodies to provide affinity-based isolation of CTCs. Channel 
width, which is similar to an average CTC diameter (12–25 µm), plays a critical role in 
maximizing the probability of cell/wall interactions and allows for achieving high CTC recovery. 
The extended channel depth allows for increased throughput at the optimized flow velocity (2 
mm/s in a microchannel); maximizes cell recovery, and prevents clogging of the microfluidic 
channels during blood processing. Fluidic addressing of the microchannel array with a minimal 
device footprint is provided by large cross-sectional area feed and exit channels poised orthogonal 
to the network of the sinusoidal capillary channels (so-called Z-geometry). Computational 
modeling was used to confirm uniform addressing of the channels in the isolation bed. Devices 
with various numbers of parallel microchannels ranging from 50 to 320 have been successfully 
constructed. Cyclic olefin copolymer (COC) was chosen as the substrate material due to its 
superior properties during UV-activation of the HAR microchannels surfaces prior to antibody 
attachment. Operation of the HT-CTC device has been validated by isolation of CTCs directly 
from blood secured from patients with metastatic prostate cancer. High CTC sample purities (low 
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number of contaminating white blood cells, WBCs) allowed for direct lysis and molecular 
profiling of isolated CTCs.
1. Introduction
Deaths from cancer typically result from metastatic disease; in fact, 90% of all cancer-
related deaths result from metastatic disease. For most solid tumors, metastasis arises from 
the release of cancer cells entering into circulation (circulating tumor cells, CTCs). The 
resultant CTCs are thought to reflect the genetic and phenotypic diversity of the tumor and 
evolve in a manner reflecting the progression from the primary to metastasis (Hou et al. 
2010). They can be found in most patients with solid tumors using current isolation methods 
(Allard et al. 2004). However, patients with more advanced disease have a higher CTC 
number (Nakagawa et al. 2007). CTCs in breast cancer patients are present in the blood in 
numbers that range from one to hundreds per mL (Yang et al. 2009), yet elevated leukocyte 
counts into the isolated fractions (i.e., low purity) may preclude securing high quality 
molecular data from these CTC fractions (Smirnov et al. 2005; Maheswaran and Haber 
2010; Farace et al. 2011).
The main challenge associated with the analysis of CTCs is their low frequency in a high 
background of spectator cells (i.e., hematopoietic cells). Highly sensitive and specific 
enrichment techniques are required to enable effective CTC clinical analysis, especially 
molecular analysis. Three important metrics are considered when evaluating CTC 
enrichment techniques; (i) throughput, defined as the maximum volume processing rate; (ii) 
recovery, an indicator of the number of target cells selected from the input sample with 
respect to the seed level of the target in that same sample; and (iii) purity defined as the ratio 
of CTCs selected to the total number of cells enriched.
Johnson and Johnson’s Veridex CellSearch™ is an FDA 510K cleared technology for CTC 
enrichment. It has begun clinical trials in breast, prostate and colorectal cancers, although it 
is not yet part of any conventional treatment or diagnostic protocol. The CellSearch™ 
system uses functionalized immunomagnetic beads that target the tumor specific antigen, 
epithelial cell adhesion molecule (EpCAM), often associated with CTCs. The CellSearch™ 
system has been publicized and validated for clinical trial purposes, yet low purity (0.01–
0.1%) and poor clinical sensitivity are known inadequacies. Recent data has shown that 7/9 
normal-type breast cancer cell lines could not be recovered using the CellSearch system 
(Sieuwerts et al. 2009; Mostert et al. 2011). In addition sample pre-processing steps are 
laborious and lengthy, generating long assay turnaround times. Furthermore, assay kit costs 
are very high. Thus, new, more efficient, and less expensive technologies that can provide 
similar or higher CTC sensitivity and specificity will be competitive in the medical device 
marketplace.
CellSearch typically recovers fewer CTCs from clinical samples than newer platforms, such 
as those based on microfluidics, which can directly process whole blood and isolate CTCs 
with high recovery (Kuo et al. 2010; Lin et al. 2009; Dharmasiri et al. 2010; Maheswaran et 
al. 2008; Xu et al. 2009; Adams et al. 2008; Tan et al. 2009; Nagrath et al. 2007; Dharmasiri 
et al. 2009). Microfluidic devices are attractive platforms for the analysis of CTCs for 
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several reasons: (i) They can be configured to select CTCs based on several different 
modalities including biological cell properties, such as expression of antigens specific to the 
CTC type, or physical cell properties, such as size (Williams et al. 2012). (ii) Microfluidic 
devices operate in a closed architecture, minimizing the potential of sample contamination 
artifacts that may provide false positive results, especially in clinical laboratory settings. (iii) 
Microfluidic devices can be produced in a high production mode and at low-cost. For 
example, devices can be produced in thermoplastics using micro-replication, the same 
technology used to produce consumables such as CD and DVDs (Adams et al. 2008; 
Dharmasiri et al. 2009; Dharmasiri et al. 2011). (iv) CTC selection devices can be integrated 
to other processing steps to fully automate sample processing, negating the need for operator 
intervention and thus, minimizing false negative results.
Microfluidic devices using affinity-based assays typically demonstrate higher purities 
compared to those based on size differences between the CTCs and blood cells but at the 
expense of throughput (Adams et al. 2008; Nagrath et al. 2007; Saliba et al. 2010; 
Dharmasiri et al. 2011). CTC affinity beds in microfluidic platforms have employed a 
variety of geometrical configurations (e.g. arrays of microposts, high aspect ratio 
microchannels, nanotextured channels, herringbone designs) to optimize recoveries (Adams 
et al. 2008; Dharmasiri et al. 2011; Nagrath et al. 2007). A CTC chip utilizing a staggered 
arrangement of microposts produced a recovery of 65% at low shear (0.4 dynes/cm2) with a 
throughput of 1 mL/h (Nagrath et al. 2007), while herringbone channels are found to induce 
chaotic mixing leading to recoveries on the order of 91% and purities from 9% to 14% (Stott 
et al. 2010). Recently, a nanotextured herringbone device consisting of silicon nanopillars 
poised on a fluidic channel was reported (Wang et al. 2011). A flow rate of 1 mL/h was used 
for CTC selection from clinical samples. Adams and coworkers utilized sinusoidal high 
aspect ratio microchannels to reduce pressure drops and improved throughput for positive 
selection (1.6 mL/h). A recovery of MCF 7 cells spiked into blood was reported to be 97% 
(Adams et al. 2008).
Herein, we demonstrate a novel high-throughput (HT) CTC isolation device consisted of a 
parallel array of high aspect ratio (HAR) sinusoidal microchannels with nominal dimensions 
of 25 µm × 150 µm × 30 mm arranged in a Z-configuration. The high aspect ratio of the 
microchannels allowed short assay times for processing blood samples while maintaining 
the optimum average fluid velocity of 2 mm/s for maximum recovery and at a CTC capture-
enhancing channel width of 25 µm. The Z-type arrangement of the inlet and outlet channels 
occupied a smaller footprint compared to our previously reported CTC capture device 
(Adams et al. 2008; Dharmasiri et al. 2011), allowed for uniform addressing of parallel 
microchannels, and easy scaling of the CTC isolation bed to accommodate larger number of 
microchannels to further increase device throughput. Furthermore, it improved the control of 
HT-CTC device operation by providing high linear fluid velocities in the inlet and outlet 
channels, which efficiently removed persistent air bubbles that are inevitably introduced into 
device architectures during operation. We present the results of the fabrication and 
characterization of the HT-CTC chips in polymers via hot-embossing and discuss our 
studies on proper material selection for chip construction with respect to the efficiency of 
antibody attachment to the microchannel surface. Finally, we demonstrate the utility of the 
device by isolating CTCs directly from blood samples from patients with metastatic prostate 
Hupert et al. Page 3






















cancer and conduct molecular profiling of the selected CTCs, which was enabled by the high 
purity of the selected fractions.
2. Design of the HT-CTC chip
2.1 Design of CTC isolation bed
The design of the HT-CTC chip is presented in Fig. 1(a). It consisted of a CTC isolation bed 
composed of a parallel array of sinusoidal microchannels with nominal dimensions of 25 µm 
width, 150 µm depth, and 30 mm length and inlet and outlet channels arrange in a so called 
Z-configuration. The geometry of the CTC isolation bed is modeled on recent studies by 
Adams et al. and Dharmasiri et al., who have successfully demonstrated use of a network of 
parallel sinusoidal microfluidic channels decorated with anti-EpCAM monoclonal 
antibodies (mAbs) for efficiently isolating CTCs directly from blood inputs (Adams et al. 
2008; Dharmasiri et al. 2009). The use of the sinusoidal channel geometry provided higher 
recovery compared to straight channels of the same dimensions. This was attributed to 
escape of the CTCs’ travel from flow streamlines associated with fully developed laminar 
flow and the Fahraeus-Lindqvist effect (cell focusing to channel centroid), which can be 
overcome for sinusoidal-shaped channels resulting in a higher probability of cell/wall 
interactions (Adams et al. 2008). These studies also indicated two other important findings 
regarding the design of the CTC isolation bed and optimum operating conditions that needed 
to be considered to achieve maximum cell recoveries. Firstly, at least one dimension of the 
microchannel must be close to the average diameter of the CTCs (12–25 µm) to promote 
cell-wall interactions. Secondly, there is an optimal linear flow velocity (2 – 2.5 mm/s) of 
the CTCs through the microchannels that supports high recoveries. At higher flow 
velocities, the short residence time of CTC membrane antigens with the surface capture 
antibodies limits CTC isolation (Adams et al. 2008; Chang and Hammer 1999; Nagrath et al. 
2007).
Given these design rules, it was clear that increasing the throughput of the CTC isolation 
device can be accomplished by increasing the aspect ratio of the sampling channels while 
keeping their width constant and/or increasing the number of parallel channels in the 
isolation bed. Fig. 1(b) illustrates an HAR channel with dimensions comparable to a typical 
CTC but larger than an average WBC. The effect of the number of microchannels 
comprising the isolation bed and their aspect ratio on the time required to process 7.5 ml of 
blood through the HT-CTC device at the optimal flow velocity is demonstrated in Fig. 1(c). 
Clearly, high aspect ratio microchannels offer a practical solution for increasing the 
throughput. For example, the device originally reported by Adams et al. (Adams et al. 2008) 
used 51 parallel channels (cross-section 30 µm × 150 µm) and would require nearly 4.7 h to 
process 7.5 ml of blood. By increasing the number of channels to 500 and depth to 250 µm, 
the same input volume could be processed in <17 min using the same average linear velocity 
of 2 mm/s. One should also note that high aspect ratio microchannels with aspect ratio equal 
to AR could not be simply replaced by low aspect ratio microchannels with aspect ratio 
equal to 1/AR; the beneficial effect of the sinusoidal geometry would be negated.
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2.2. Design of inlet and outlet channels – Z-configuration
Previously reported studies have utilized triangular inlet/outlet regions to address the parallel 
channels in the CTC isolation bed (Fig. 2) (Adams et al. 2008; Dharmasiri et al. 2009). 
Critical to device efficiency, flow through the capture channels should be uniform, 
remaining at a linear velocity of 2 mm/s to optimize CTC recovery (Adams et al. 2008; 
Dharmasiri et al. 2009; Chang and Hammer 1999). Using CFD simulations of a numerically 
tractable model, where triangular inlet/outlet regions connected 51 sinusoidal channels, we 
validated that flow is clearly uniformly distributed in the previously reported device, only 
deviating slightly through the outer channels, where viscous drag along the inlet/outlet walls 
by the no-slip condition reduced flow velocity (Fig. 2a). Practically, however, the fluid’s 
velocity through the relatively large, triangular regions is slow (roughly 0.2 mm/s) compared 
to the capture channels, and we have observed that pressure differences within these regions 
were not great enough to displace air bubbles inadvertently introduced into the system 
during operation (Fig. 2(b)). The presence of air bubbles can disrupt optimal flow 
distribution and decrease the efficiency of CTC capture. We have also observed that CTCs 
as well as contaminating WBCs were occasionally non-specifically trapped around the air-
liquid interface at the bubble surface and were difficult to control during subsequent 
processing steps, such as bed washing and cell staining. For example, CTCs that were not 
bound to the surface via antigen-antibody interactions could be lost during bed washing at 
higher flow rates, thus negatively impacting the recovery, whereas some WBCs adhering to 
the surfaces in the triangular inlet/outlet were not efficiently removed from the device due to 
lower shear stress observed in these sections, which led to overall lower purity. These 
aspects were of considerable concern for isolation beds comprised of larger numbers of 
parallel microchannels.
To alleviate these issues, we adopted herein another fluidic architecture to uniformly address 
a large array of parallel microchannels within the selection bed, the so called Z-
configuration (Figs 1(a) and 2(c)). The Z-configuration is a geometry well known in the 
field of fuel cells (Zhang et al. 2009). In this configuration, fluid enters the selection bed 
through a single inlet channel poised perpendicular to an array of microchannels comprising 
the CTC isolation bed and exits also through a single outlet channel that is also 
perpendicular to the sinusoidal microchannels. The Z-configuration provides the smallest 
possible footprint for addressing the isolation bed of the device as only two microchannels 
are added to the footprint of the selection bed independent of the number of channels being 
addressed. For example, in a recently proposed fluidic design for neutrophil isolation (Kotz 
et al. 2010), bifurcation was used for addressing parallel channels of the isolation bed. Using 
this design, the footprint of the proposed device nearly doubled in order to allocate space for 
the fluid distribution network.
Because the Z-configuration is a highly parallel system, flow distribution is uniquely 
sensitive to the length and number of capture channels; thus, a smaller, numerically tractable 
CFD model as the one used for the triangular inlet/outlet simulations described above is not 
representative of the Z-configuration shown in Fig. 1(a). To analyze the Z-configuration 
device, we have employed a mathematical model that segments the system into individual, 
interconnected fluidic resistors and accurately solves for flow distribution by 
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conglomerating the pressure and mass balance equations governing flow through each 
resistor (Zhang et al. 2009). From Fig. 2(a), it is clear that flow in the Z-configuration is also 
uniformly distributed. Here, the slight parabolic skew occurs by an entirely different 
phenomenon than viscous drag (Zhang et al. 2009). In this sense, the Z-configuration’s 
primary advantage is that flow through the inlet/outlet channels is typically faster than 2 
mm/s, ensuring sufficient pressure to remove any air bubbles introduced during processing 
(Fig. 2(c)) and optimal flow is maintained throughout the entire analysis process. 
Furthermore, just as the high aspect ratio capture channels enable faster sample processing, 
it is possible to further increase volumetric throughput by arraying additional high aspect 
ratio channels in a Z-configuration without sacrificing device footprint (Kamande et al. 
2013).
3. Fabrication and characterization of HT-CTC chips
Application of the HT-CTC devices presented herein for clinical testing required that they 
are manufactured as disposable units in order to avoid sample carry-over and cross-
contamination artifacts during analysis. This requirement required that the chips needed to 
be produced in high volumes and at low unit costs to be successfully implemented for 
clinical testing (Chin et al. 2012). Micromanufacturing techniques using polymer substrates 
fulfill these requirements as polymers are generally inexpensive and a variety of low-cost 
fabrication techniques are available for both rapid prototyping and mass production of 
finished devices and with high aspect ratio (Becker and Gartner 2000; Becker and Locascio 
2002; Soper et al. 2000). Significant cost advantages as compared to other polymer 
microfabrication techniques can be realized when using replication techniques such as 
casting, hot embossing, or injection molding. Among the replication techniques, injection-
molding is considered to be the least expensive for mass production of devices. However, it 
also carries the highest initial capital costs associated with mold master fabrication, machine 
set-up, and molding condition optimization (Becker and Gartner 2000). For the purpose of 
the research presented herein, we employed hot embossing as the approach for fabrication of 
the HT-CTC devices. It is important to realize that microfluidic devices developed using hot 
embossing can be transferred into production via injection molding with relative ease as the 
same thermoplastic polymers are used and similar design rules need to be followed during 
device development. This approach avoids or at least minimizes well recognized problems 
in the future associated with transferring academic ideas into manufacturable products due 
to incompatibility of the materials and microfabrication methods between early development 
and high-volume production (Chin et al. 2012).
The first step in microfabrication of microfluidic devices using hot-embossing is the 
fabrication of the molding master. Herein, the molding master was fabricated in brass via 
high-precision micromilling (HPMM) using a commercial milling machine (KERN 44, 
KERN Micro- und Feinwerktechnik GmbH & Co.KG; Murnau, Germany) and solid carbide 
tools (500 µm, 200 µm, and 100 µm diameter (Performance Micro Tool, Janesville, WI )) 
using procedures previously described in detail (Hupert et al. 2007). Briefly, the surface of a 
6.3 mm thick, 120 mm diameter circular brass plate (alloy 353 engravers brass, McMaster-
Carr, Atlanta, GA) was pre-cut with a 500 µm diameter milling bit to ensure parallelism 
between both faces of the brass plate and uniform height of the final milled microstructures 
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over the entire pattern. This was followed by a rough milling of the microstructures using a 
500 µm and 200 µm milling bits, and a finishing cut with either 200 µm or 100 µm diameter 
milling bit depending on the smallest distance between milled structures. Micromilling was 
carried at 50,000 rpm at feed rates that were dependent on the size of the milling bit and 
were typically in the range of 200 mm/min for a 500 µm bit, 100 – 150 mm/min for 200 µm 
bit, 50 – 75 mm/min for 100 µm bit.
HPMM offers significant advantages over other mold master fabrication methods such as X-
ray-LiGA or UV-LiGA as it allows for shorter turnaround times, low cost, and single step 
fabrication of multi-level structures (Becker and Locascio 2002; Soper et al. 2000; Hupert et 
al. 2007). Although HPMM is not capable of achieving the fine resolution or minimum 
feature size of lithography-based techniques (i.e., sub-µm for X-ray LiGA) due to milling bit 
size limitations, it is well suited for many microfluidic applications, which usually require 
structures in the range of 10 – 500 µm with aspect ratios (<20) and inter-structure spacing 
(>30 µm) easily obtainable using micromilling, such as that required for the CTC selection 
device shown in Fig. 1 and 2. Fig. 3(a) presents the brass mold master used for replication of 
the HT-CTC beds with 50, 100, and 150 sinusoidal channels. Fig. 3(b) presents an example 
of multilevel structures used to replicate receiving ports (Fig. 3(c)) required for mounting 
capillary tubing for minimal stress applied to the blood sample during introduction into the 
microfluidic network. Fig. 3(d) presents a picture of assembled HT-CTC devices, which 
could be scaled from 50 to 320 microchannels depending on the blood volume processing 
needs while keeping the processing time below 45 min irrespective of the input volume.
HT-CTC chips were replicated into cyclic olefin copolymer (Topas 6013)S-04, Topas 
Advanced Polymers, Florence KY) using hot embossing (HEX-03, Jenoptik Optical 
Systems GmbH, Jena, Germany) at the following conditions: embossing temperature 155°C, 
embossing force 30 kN, embossing time 120 s, de-molding temperature 122 °C. Fig. 4 
presents SEM images of hot embossed HT-CTC beds. Clearly, high quality replication of 
the HAR microchannels (AR = 6) was achieved. The average dimensions for the sinusoidal 
microchannels were as follows: width measured at the bottom of the microchannel (WB) 
was 20.0 ± 1.0 µm; width measured at the top (WT) was 27.4 ± 0.8 µm and microchannel 
depth was (D) was 152.0 ± 1.0 µm. The dimensions indicate a trapezoidal shape of the 
channel cross-section with slightly tapered walls with an average draft angle of 1.4°. This 
draft angle was not intentionally imposed by the mold fabrication because straight (not 
tapered) milling bits were used during molding master fabrication. It was rather the result of 
selected milling conditions and flexing of the micromilling tools during brass removal. Draft 
angles of this magnitude are very advantageous for the replication process as they reduce 
friction between the molded part and mold master during de-molding, thus reducing 
replication errors due to polymer pull-out and prolonging the molding master usable 
lifetime.
SEM investigation of the sidewalls of the microchannels also revealed the presence of the 
characteristic side wall roughness, which was a direct result of using a micromilled brass 
molding master for hot embossing (inset in Fig. 4(b)). This roughness was caused by 
transfer of the milling marks left on the sidewalls of the brass microstructures from the 
milling process by the imperfections of the cutting edge of the milling bit (Hupert et al. 
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2007). The milling marks propagate in the same direction as the milling bit movement 
(parallel to the molding master floor) and lead to different sidewall roughness measured in a 
horizontal direction versus one measured vertically. The typical values for sidewall 
roughness were 55 nm average roughness (Ra) and 200 nm mean peak height (Rpm) when 
measured horizontally along the channel wall, and 115 nm and 290 nm for Ra and Rpm, 
respectively, when measured vertically (Hupert et al. 2007). For comparison, the typical Ra 
of the polymer material used as the stock for hot embossing was less than 20 nm.
It has been reported that sidewall roughness larger than 80 nm RMS (or ~73 nm Ra) is 
detrimental to the quality of the hot embossed structures and long term stability of molding 
masters for micro-replication of the structures with aspect ratios above 0.5 (Becker and 
Heim 2000) for highly vertical sidewalls such as those produced with the LiGA process 
(Yuhua et al. 2007). Interestingly, the sidewall roughness of this magnitude observed in our 
studies had no noticeable effect on the replication fidelity of the HAR channels (AR = 6) 
and mechanical and dimensional stability of the molding master over prolonged use, which 
is probably due to the beneficial effect of the 1.4° taper observed for microstructures 
produced via HPMM. To date, we were able to successfully perform over 500 replication 
cycles using a single brass mold master without a noticeable reduction of the quality of the 
embossed structures or deterioration of the master. For example, the average microchannel 
dimension measured after the first 30 embossing cycles were 20.0 ±1 µm × 27.4 ±0.8 µm × 
152 ±1 µm (WB × WT × D), whereas the corresponding dimensions for the microchannels 
measured after 300 embossing cycles were 19.7 ± 0.5 µm × 27.8 ± 1.0 µm × 152 ±1 µm. 
Clearly, measured dimensions of the HAR microchannels are well within the measurement 
error indicating high dimensional stability of the molding master and long term 
reproducibility of the hot embossing process.
Following hot embossing, the next step in device fabrication is enclosing the fluidic network 
with a cover plate made from the same material as the substrate, in this case COC. The 
process we employed herein is thermal fusion bonding in which the cover plate and 
substrate, following UV activation (see below) are brought into conformal contact under a 
fixed pressure and then slowly heated to a temperature slightly below the Tg of the 
thermoplastic. Specifically, we used a temperature of 132°C and a bonding pressure of ~1 
N/cm2. Bonding conditions were carefully selected to achieve high bond strength, but 
preserve as much as possible structural integrity of the HAR microchannels. Comparison of 
Fig. 4(c) and Fig. 4(d) shows that slight deformation of the HAR microchannel was 
observed during the thermal fusion bonding process as noted in the inset of Fig. 4(d).
4. Modification of High Aspect Ratio, Polymeric Microstructures for the 
Immobilization of Antibodies
Critical to the positive selection of CTCs in our devices and many bioassays in general, 
recognition elements must be appropriately attached, preferably via covalent interactions, to 
surfaces within the HAR sinusoidal microchannels. While several avenues for such 
attachments are possible, the method most compatible with mass producible polymer 
devices is the irradiation of selection surfaces with UV light to generate carboxylic acid 
groups that are reactive to amine-bearing biologics, such as monoclonal antibodies. This UV 
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activation modality has been studied extensively for a number of thermoplastics (McCarley 
et al. 2005), but only recently has the UV activation of high aspect ratio, polymer 
microchannels been investigated (Jackson et al. 2013). To activate the HAR microchannel 
surfaces, the majority of the UV radiation’s flux must first pass through the bulk material. 
Thus, the optimal transmissivity of the polymeric substrate is critical, especially as the 
microchannel’s aspect ratio increases (Jackson et al. 2013).
We studied this effect for two polymers, PMMA and COC. Transmissivity of PMMA 
measured at 254 nm (T254nm) has shown poor characteristics as it has changed from 1.2 to 
0.5 % over the course of a 15 min UV activation time using a low pressure, broadband Hg 
lamp with power density of 22 mW/cm2 measured at 254 nm. On the other hand, COC has 
shown excellent optical properties as the T254 nm changed from 53.8 to 36.8 % during the 
same course of UV treatment. Next, within UV-activated and thermal fusion bonded 
microchannels, we reacted fluorescently labeled Cy3-oligonucleotides with surface-confined 
carboxylic acids via a 5’-pendant amino group on the oligonucleotide, thereby measuring 
activation efficiency via fluorescence intensity. The fluorescence signal within COC 
microchannels was 4.68 ±0.80 times greater than PMMA microchannels as acquired through 
the assembled microdevices’ cover plate (Fig. 5). We then exposed the microchannel 
sidewalls by cutting along their lengths with a band saw and observed an intriguing effect of 
the bulk polymer’s absorption of UV radiation (Fig. 6). An activation gradient was observed 
along the depth of the PMMA sidewalls, decreasing from 384 ±81 cps in the top third of the 
channel to nearly background fluorescence below (112 ±55 cps). In the case of the COC 
microchannel, the degree of activation as noted by the fluorescence intensity was 
significantly greater and more uniform throughout its depth (2233 ±310 cps). The impact of 
these observations culminated in an increase in both the recovery and purity of CTC capture 
using CTC isolation units fabricated in COC polymer as opposed to PMMA (Jackson et al. 
2013). Based on these findings, we selected COC as the primary material for fabrication of 
the HT-CTC chips. All clinical studies reported below were performed using this material.
5. Isolation of CTCs from cancer patients
As a demonstration of the utility of the HT-CTC device for isolating CTCs from blood, we 
processed blood samples spiked with cultured MCF7 cells and blood samples secured from 
patients with metastatic prostate cancer. First, the surface of the microfluidic channels of UV 
activated and assembled COC HT-CTC devices was modified using well established EDC-
NHS chemistry (20 mg/ml EDC, 2 mg/ml NHS, in 100 mM MES, pH 5.2) followed by the 
incubation with a solution of anti-EpCAM monoclonal antibody (0.5 mg/ml; 150 mM PBS 
buffer, pH 7.4) overnight at 4°C (Adams et al. 2008). This activation protocol produced the 
surfaces of microchannel with covalently bound anti-EpCAM antibodies in near monolayer 
coverage, which is required for selective affinity-based isolation of CTC expressing EpCAM 
antigens. Blood was processed through the device using a volumetric flow rate of 23 µL/min 
required to achieve a 2 mm/s average sample flow velocity in the sinusoidal microchannels. 
After isolation and washing, captured cells were fixed (2–4% paraformaldehyde), 
permeabilized (0.1% Triton X-100), and stained using a standard panel of fluorescently 
labeled markers commonly used for CTC analysis including epithelial markers (Texas Red-
labeled anti-Cytokeratins 7/8/pan), nucleus stain (DAPI), and a negative control consisting 
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of FITC labeled leukocyte antibody CD45; the stained cells were characterized using 
fluorescence microscopy.
Fig. 7(a) presents fluorescence images of MCF7 cells captured within the sinusoidal 
channels of the isolation bed. Two prostate cancer CTCs are shown in Fig.7(b) and display 
the necessary characteristics of CTCs, including positive staining for DAPI (blue) and 
Cytokeratins (red), and lack of staining for CD45 (green) (Nagrath et al. 2007). Also the 
large nucleus to cytoplasm ratio observed for these cells is distinctive for CTCs. Fig. 7(c) 
shows a summary of the number of CTCs and contaminating WBCs isolated from blood 
samples from 9 patients with prostate cancer who donated their blood under a protocol 
approved by the University of North Carolina Institutional Review Board. The number of 
CTC detected per 1 ml of blood ranged from 19 to 76 (average = 39 ±19) whereas the 
number of contaminating WBCs was much lower and relatively stable between all analyzed 
samples (range 2 to 8, average = 6 ±2). These data indicate very high purity of isolated 
CTCs with the average purity expressed as the ratio between number of CTCs and the total 
number of CTCs and WBCs (purity = 86 ± 6%). We believe that such high purity was a 
direct result of well controlled, high shear forces acting on the non-specifically bound 
WBCs during the bed washing step.
Given such high purity of the selection process, we attempted to molecular profile the 
isolated CTCs. For this, 2.5 ml of patient blood was processed through the anti-EpCAM 
modified HT-CTC chip, washed with PBS buffer, and the total RNA from the cells captured 
was extracted and purified using a commercial RNeasy micro kit (Qiagen) with a slightly 
modified protocol. The reverse transcription was performed using SuperScript III reverse 
transcriptase (Invitrogen) and an aliquot of purified RNA. Finally, the resulting cDNA 
underwent a PCR using 6 sets of primers targeting GAPDH (housekeeping gene control), 
PSMA (prostate-specific membrane antigen), PSA (prostate-specific antigen), CK19, 
androgen receptor, and EpCAM. As expected, PSMA, PSA, androgen receptor, and EpCAM 
show strong bands while there was no band for the CK19 gene indicating that successful 
molecular profiling can be achieved on the population of CTCs isolated directly from the 
patient blood using the HT-CTC device.
6. Conclusions
We have developed and tested disposable, all-polymer, microfluidic device for efficient, 
high-throughput isolation of CTCs directly from blood. The device employed isolation bed 
consisting of an array of HAR, parallel, sinusoidal microchannels with walls covalently 
decorated with anti-EpCAM antibodies to provide selective, affinity-based capture of CTCs. 
We have successfully adopted Z-configuration of inlet and outlet channels to uniformly 
address CTC isolation bed and eliminate presence of persistent air bubbles that may affect 
analytical performance of the device. We have also evaluated PMMA and COC as substrate 
materials for construction of HT-CTC devices and shown that COC possesses superior 
optical properties for efficient UV activation of HAR microfluidic channels, which result in 
higher density and more uniform coverage of the microchannel surface with antibodies. 
Finally, we have tested the device utility by isolating CTCs directly from blood from 
patients with metastatic prostate cancer, and molecular profiling of isolated CTCs.
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(a) Schematic representation of the design and operation of the HT-CTC selection chips 
arranged in a Zconfiguration. (b) Diagram of size comparison between microfluidic channel 
dimensions and the size of a typical CTC and WBC. (c) Processing time for 7.5 ml of blood 
as a function of the microchannel depth and channel number for a channel width of 25 µm 
and linear flow velocity of 2 mm/s.
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Comparison between different inlet/outlet geometries for a CTC microfluidic chip. (a) 
Results of computer simulations for the distribution of flow velocities within the CTC 
isolation bed with 50 microchannels arranged in a Z-configuration or 51 microchannels with 
triangular inlets and outlets. Pictures of CTC capture beds filled with blood for the triangular 
configuration (b) and the Z-configuration (c).
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(a) Picture of a high-precision micromilled brass mold master (120 mm diameter) for hot-
embossing HT-CTC chips with 50, 100, and 150 sinusoidal microchannels (microchannel 
nominal dimensions were 25 µm × 150 µm × 30 mm (WxDxL) and microchannel spacing 
was 330 µm center-to-center. (b and c) SEM of a section of the mold master and hot 
embossed COC HT-CTC selection chip. (d) Assembled HT-CTC chips with different 
numbers of microfluidic channels designed for efficient processing of different sample 
volumes. (I-III) show chips fabricated using mold insert shown in (a); IV – shows a CTC 
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chip with reduced microchannel spacing (200 um center to center) and single microchannel 
length of 20 mm which allowed to fit 320 sinusoidal channels within a footprint of a 
standard microscope slide (25 mm × 75 mm). Various interconnection strategies for sample 
introduction are also shown.
Hupert et al. Page 17























SEMs of the HT-CTC chips hot embossed into the thermoplastic, COC. (a) Low resolution 
SEM showing a series of sinusoidal HAR channels. (b) High resolution SEM image of one 
sinusoidal channel with the inset showing surface roughness due to milling. (c) SEM of the 
HAR sinusoidal channel prior to thermal fusion bonding of the cover plate. (d) SEM of a 
HAR channel following thermal fusion bonding of hot embossed HT-CTC chip with the 
COC cover plate and dicing to reveal microchannel cross-section. Burrs visible on the right 
side of the microchannel wall (inset) resulted from the dicing process.
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Fluorescence imaging of the (a) PMMA and (c) COC HAR microchannels after UV 
activation and chemical attachment of dye-labeled oligonucleotides (20 mg/mL EDC, 40 µM 
oligo-Cy3, pH 7.4, 3 h, RT). Fluorescent intensity of immobilized oligonucleotides indicate 
activation efficiency within high aspect ratio microstructures. (b) PMMA and (d) COC contr 
ols (oligonucleotides introduced without EDC coupling agent) show low nonspecific 
adsorption and autofluorescence.
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Uniformity of the COC and PMMA HAR microchannel modification. (a) Schematic 
representation of how the modified chip was cut to reveal cross-section for fluorescent 
measurement shown in (b). (b) Fluorescence imaging of the COC HAR microchannels after 
UV activation and chemical attachment of dye-labeled oligonucleotides (conditions as in 
Fig. 5) and schematic representation of cut to reveal side view of the modified channel 
shown in (c). (c) and (d) Magnified fluorescence images of modified HAR microchannel for 
COC and PMMA, respectively.
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Isolation and analysis of CTCs using HT-CTC device. (a) Image of MCF7 cells isolated 
using antiEpCAM modified isolation bed and stained with molecular stain DAPI. (b) 
Fluorescence image of two CTCs isolated from blood secured from patient with prostate 
cancer. CTCs demonstrated characteristic positive staining for molecular marker DAPI 
(blue) and cytokeratins (red) and negative staining for CD44. (c) Summary of CTC isolation 
data for patients with prostate cancer. High purity of isolate sample is evident by low 
numbers of co-isolated leukocytes. (d) Results showing the molecular profiling of 
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EpCAM(+) CTCs. In this case, the total RNA was extracted from the CTCs, with the mRNA 
reverse transcribed into cDNA using dT primers and then subjected to PCR with the gene 
specific primers.
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